1333127-18-6

Basic information

• Product Name: N-(5-chloropyridine-2-yl)-2-[4-(trifluoroacetyl(methyl)amino)-2-(3-(trifluoroacetylamino)propoxy)phenylcarbonylamino]-5-methoxybenzamide
• Synonyms: N-(5-chloropyridine-2-yl)-2-[4-(trifluoroacetyl(methyl)amino)-2-(3-(trifluoroacetylamino)propoxy)phenylcarbonylamino]-5-methoxybenzamide
• CAS NO: 1333127-18-6
• Molecular Weight: 675.972
• Mol File: 1333127-18-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: N-(5-chloropyridine-2-yl)-2-[4-(trifluoroacetyl(methyl)amino)-2-(3-(trifluoroacetylamino)propoxy)phenylcarbonylamino]-5-methoxybenzamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(5-chloropyridine-2-yl)-2-[4-(trifluoroacetyl(methyl)amino)-2-(3-(trifluoroacetylamino)propoxy)phenylcarbonylamino]-5-methoxybenzamide(1333127-18-6)
• EPA Substance Registry System: N-(5-chloropyridine-2-yl)-2-[4-(trifluoroacetyl(methyl)amino)-2-(3-(trifluoroacetylamino)propoxy)phenylcarbonylamino]-5-methoxybenzamide(1333127-18-6)

Safety Data

• Hazardous Substances Data: 1333127-18-6(Hazardous Substances Data)

Upstream product

• 1333127-10-8 2-[3-aminopropoxy]-4-(methylamino)benzoic acid 
• 1333127-09-5 2-[3-(acetylamino)propoxy]-4-(methylamino)benzoic acid 
• 1333127-08-4 2-[3-(acetylamino)propoxy]-4-aminobenzoic acid 
• 1333127-07-3 2-[3-(acetylamino)propoxy]-4-[(tertbutoxycarbonyl)amino]benzoic acid 
• 184033-42-9 4-[(tert-butoxycarbonyl)amino]-2-hydroxybenzoic acid 
• 280773-17-3 2-amino-N-(5-chloro-pyridin-2-yl)-5-methoxy-benzamide 
• 1333127-11-9 2-[3-(trifluoroacetylamino)propoxy]-4-[trifluoroacetyl-(methyl)amino]benzoic acid 
• 65-49-6 4-Aminosalicylic acid 

Downstream Products

• 1333127-19-7 N-(5-chloropyridine-2-yl)-2-[4-(methylamino)-2-(3-aminopropoxy)phenylcarbonylamino]-5-methoxybenzamide 
• 1333126-86-5 N-(5-chloropyridine-2-yl)2-[4(ethaneimidoylmethylamino)-2-(3-aminopropoxy)phenylcarbonyl-amino]-5-methoxybenzamide 

Relevant articles and documents

URETHANES, UREAS, AMIDINES AND RELATED INHIBITORS OF FACTOR XA

The invention relates to a new class of compounds, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions that are effective as selective inhibitors of factor Xa, both in the isolated state and in a complex with other proteins. The compounds of the invention can be used for treating and preventing diseases, such as acute coronary syndrome, myocardial infarction, unstable angina, refractory angina, thromboses caused by post-thrombolytic therapy or coronary angioplasty, acute ischemia mediated cerebrovascular syndrome, embolic stroke, thrombotic stroke, and other diseases in humans and other mammals associated with blood coagulation problems.